{"id":"comparator-losartan-hctz","safety":{"commonSideEffects":[{"rate":"5–10%","effect":"Dizziness"},{"rate":"3–5%","effect":"Fatigue"},{"rate":"5–10%","effect":"Hyperuricemia (HCTZ-related)"},{"rate":"5–15%","effect":"Hypokalemia (HCTZ-related)"},{"rate":"<2%","effect":"Cough (less common with ARB than ACE inhibitor)"},{"rate":"2–5%","effect":"Hyperglycemia (HCTZ-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan selectively blocks AT1 angiotensin II receptors, preventing the hormone's vasoconstrictive and sodium-retaining effects, thereby reducing blood pressure and protecting target organs. Hydrochlorothiazide (HCTZ) inhibits sodium reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion to decrease blood volume and pressure. The combination provides complementary mechanisms for enhanced antihypertensive efficacy.","oneSentence":"Losartan is an angiotensin II receptor antagonist that blocks vasoconstriction and aldosterone secretion to lower blood pressure; HCTZ is a thiazide diuretic that reduces fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:04.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (as combination therapy or monotherapy with losartan)"}]},"trialDetails":[{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":"Hypertension","enrollment":808},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840},{"nctId":"NCT00289887","phase":"PHASE3","title":"Obese Hypertension Study (0954-315)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypertension","enrollment":261},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122},{"nctId":"NCT00617877","phase":"NA","title":"Antihypertensive Response to Losartan and Genetic Polymorphisms","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hypertension","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: losartan +/- HCTZ","genericName":"Comparator: losartan +/- HCTZ","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Losartan is an angiotensin II receptor antagonist that blocks vasoconstriction and aldosterone secretion to lower blood pressure; HCTZ is a thiazide diuretic that reduces fluid volume. Used for Hypertension (as combination therapy or monotherapy with losartan).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}